Skip to main content
Story 23 October 2024
Public

Open call - Exhibit at BIO 2025 in Boston with the European Innovation Council!

BIO header
Someone

The European Innovation Council (EIC) invites EIC-backed startups and scaleups to take part in BIO 2025 and showcase their deep tech innovations in biotech. For the fourth consecutive year, the EIC will be present in the largest and most comprehensive event for biotechnology worldwide from 16-19 June 2025 in Boston, USA.

The annual BIO International Convention is the must-attend event for the biotechnology sector, with over 1,400 exhibitors and 20,000 attendees from 70 countries at the BIO 2024 edition (see video here). Key players in the biopharmaceutical industry come together to discuss market trends and foster business flows. This is accomplished, in part, by the organisation of panels and networking events and by providing access to the BIO Convention partnering platform, which facilitates the setup of B2B meetings with North American experts during the event. The trade fair will provide four days of conferences and networking opportunities to help companies forge strategic connections and appointments.

 

APPLY NOW!

If you are an EIC-backed SME, startups or scaleup and want to exhibit in BIO 2025: apply now!

Applications are open until 6 December 2024

 

What’s in it for you?

SMEs, startups, and scale-ups funded by the EIC and chosen to participate in BIO 2025 will gain exclusive access to essential business services. This includes pitching opportunities, matchmaking support, complimentary booths within the European Pavilion to showcase their innovations, and comprehensive coaching services pre-, during, and post- the trade fair. 

 

Who can apply?

BIO  2025 is looking for EIC-funded SMEs, start-ups and scale-ups working on innovative advancements in the following fields: 

  • Biomanufacturing
  • Biotechnology
  • Brain Health
  • Cell and Gene Therapies/Genome Editing
  • Chronic Diseases
  • Clinical Trials
  • Diagnostics and Personalized Medicine
  • Digital Health
  • Next Generation Biotherapeutics
  • Oncology
  • Patient Advocacy
  • Rare Diseases

 

Application 

After logging in with your EU-Login credentials, please fill in the application form and answer all the questions. 

You will be assessed on the following criteria:

  • Your plan to internationalise your innovative products and services overseas.
  • The expected impact of your participation in the trade fair.
  • The fit of your innovative products and services with the trade fair.
  • Your commitment to financial and human resources for participation in a trade fair. 
  • Your contribution to EU strategic autonomy and/or the image of the EU as a technology powerhouse.

Kindly note that the details furnished in your application form will be shared with external specialists to optimise potential benefits and ensure the efficiency of scheduled meetings.

Subsequently, the EIC ITF 3.0 team will reach out to all candidates in early January post the completion of the selection process to communicate the status of their applications.

 

About the EIC International Trade Fairs Programme 3.0

The EIC International Trade Fairs Programme 3.0 supports the internationalisation of European SMEs, scaleups and startups, building on the success of its predecessor, the EIC Overseas Trade Fairs Programme (OTF) 2.0. The Programme offers EIC awardees access to 12 diverse international trade fairs spanning EU and non-EU markets (Middle East, and the United States of America). Selected EIC-funded SMEs, startups and scaleups from EU Member States and Associated Countries have access to the Programme.   

Stay tuned on upcoming calls and find additional information and the EIC Community Platform through our news, stories and programme-related trade fairs. 

Should you have any questions on the Programme, please do not hesitate to contact us through the EIC Community Helpdesk by selecting "EVENT - EIC ITF Programme – BIO 2025" as the subject in the "Category" field.  

DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.

Please log in to see comments and contribute